Article: Schering-Plough Aims To Make CLARITIN(R) Premier Brand In OTC Category, Establish CLARINEX(R) As Premier Brand In Prescription Category.

 
   Company Reports FDA Accepts Filings of Applications 
  To Market CLARITIN Line as OTC Antihistamines 

KENILWORTH, N.J., March 8 /PRNewswire/ Schering-Plough Corporation today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing supplemental New Drug Applications (sNDAs) to switch all indications and market all formulations of the company's CLARITIN(R) (loratadine) brand of nonsedating antihistamine as over-the-counter (OTC) products.

"With the market introduction of CLARINEX(R) as the first and only prescription nonsedating antihistamine approved for the treatment of indoor and outdoor allergies, moving ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!